Open access peer-reviewed chapter

Toward Better Understanding on How Group A Streptococcus Manipulates Human Fibrinolytic System

Written By

Adam J.H. Quek, James C. Whisstock and Ruby H.P. Law

Submitted: 31 December 2018 Reviewed: 22 June 2019 Published: 14 August 2019

DOI: 10.5772/intechopen.88182

From the Edited Volume

Staphylococcus and Streptococcus

Edited by Sahra Kırmusaoğlu

Chapter metrics overview

1,053 Chapter Downloads

View Full Metrics


Group A Streptococcus pyogenes (GAS) is a human pathogen that commonly causes superficial infections such as pharyngitis, but can also lead to systemic and fatal diseases. GAS infection remains to be a major threat in regions with insufficient medical infrastructures, leading to half a million deaths annually worldwide. The pathogenesis of GAS is mediated by a number of virulence factors, which function to facilitate bacterial colonization, immune evasion, and deep tissue invasion. In this review, we will discuss the mechanism of molecular interaction between the host protein and virulence factors that target the fibrinolytic system, including streptokinase (SK), plasminogen-binding group A streptococcal M-like protein (PAM), and streptococcal inhibitor of complement (SIC). We will discuss our current understanding, through structural studies, on how these proteins manipulate the fibrinolytic system during infection.


  • hemolytic Streptococcus
  • streptokinase
  • plasminogen-binding streptococcal M protein
  • streptococcal inhibitor of complement
  • plasmin
  • host-pathogen coevolution

1. Introduction

Group A Streptococcus (GAS) is a strict human pathogen that leads to diverse clinical manifestations, ranging from superficial infections, such as pharyngitis, to severe cases of streptococcal toxic shock syndrome and necrotizing fasciitis mainly in children and young adults [1]. GAS infection can also lead to a range of post-streptococcal autoimmune sequelae such as acute rheumatic fever, rheumatic heart disease, and acute glomerulonephritis [2, 3]. Life-threatening systemic GAS infection is more prevalent in, but not limited to, regions with insufficient medical infrastructures and is estimated to cause more than half a million deaths annually worldwide [4, 5]. Through coevolution, GAS has perfected its ability to manipulate the host fibrinolytic system for invasion. In human, the plasminogen/plasmin (Plg/Plm) system plays a key role in fibrinolysis, tissue remodeling, and wound healing [6, 7, 8, 9]. This review aims to focus on the current understanding on molecular mechanisms adopted by GAS to hijack the host Plg/Plm system during infection.


2. The plasminogen/plasmin system

The early observation that streptococci stimulate fibrinolysis by Dr. William S. Tillett in 1933 [10] had triggered the subsequent discoveries on how streptococci manipulated the fibrinolytic system to facilitate blood clot dissolution [11]. The actual protein responsible for the clot lysis is in fact a constituent of the human plasma, instead of the bacteria, and is not fibrinolytic until activated by the streptococcal protein named streptokinase (SK) [12, 13]. This human lytic factor is plasmin (Plm), an activated form of plasminogen (Plg).

2.1 Structure of Plg

Plasmin (Plm) is a plasma serine protease responsible for many physiological functions such as cell migration [14], wound healing [15], inflammation [16], and prohormone processing [17]. Plm circulates in an inactive zymogen form called plasminogen (Plg).

Primarily synthesized and secreted by the liver [18], native Plg is a 89–92 kDa glycoprotein comprising of seven domains: an N-terminal PAN-apple domain (PAp), followed by five homologous kringle domains (KR-1 to KR-5) and a serine protease domain (SP) (Figure 1a) [19, 20]. The PAp domain is important for maintaining a compact conformation (closed) in the circulation [21]. Each KR domain has a lysine-binding site (LBS) that consists of the Asp-X-Asp/Glu motif (except KR-3 which has the Asp-X-Lys mutation) that recognizes and binds to surface lysine or arginine residues, such that the KR domains facilitate the binding of Plg and Plm to substrates and targets (such as fibrin and cell surface receptors) which leads to the conformational change from close to open. SP is the catalytic domain. In the zymogen form, residues His603, Asp646, and Ser741 (also called the catalytic triad) adopt an inactive configuration.

Figure 1.

The structure and function of human plasminogen (Plg). (a) Cartoon representation of the X-ray crystal structure of Plg in the closed conformation (PDB ID: 4DUR) [21]. The seven domains of Plg are the PAN-apple (PAp), kringles 1–5 (KR-1 to KR-5), and serine protease (SP) domains, shown in different colors. (b) The Plg/Plm system. Plg is converted to active plasmin (Plm) by activators, urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA), on fibrin or receptor. The activators are regulated by serine protease inhibitors (serpins), plasminogen activator inhibitors (PAI-1 and PAI-2). Plm, upon released from its site of action, is inhibited by α2-antiplasmin (α2-AP). (c) Conformational change in the SP domain during Plm formation. Superposition of the SP domains of Plg (PDB ID: 4DUR) [21] and Plm (PDB ID: 3UIR) [94] reveals the insertion and formation of a salt bridge between Val562 and Asp740 in Plm (left panel). This interaction leads to the rearrangement of catalytic triad His603, Asp646, and Ser741 (right panel) into an active conformation.

2.2 Physiological activation of Plg

In mammals, the two key physiological Plg activators are tissue-type (tPA) and urokinase-type (uPA) Plg activators (Figure 1b). Activation of Plg requires its co-localization with the activators; the expression of these activators is regulated both spatially and temporally in vivo [22, 23, 24]. Thus, Plm plays a key role in fibrinolysis intravascularly on the surface of fibrin clots in the presence of tPA and cellular migration and tissue remodeling extravascularly in the presence of uPA bound on cell surfaces.

Upon binding to the targets, Plg adopts an open conformation. The activation loop, which is obstructed by the linker between KR-3 and KR-4 in the closed conformation, becomes exposed. The activation bond (Arg561-Val562) is then proteolytically cleaved by uPA and tPA [25, 26]. The nascent N-terminal Val562 moves by 11.6 Å forming a salt bridge with Asp740; this triggers a series of conformational changes and thus allows the formation of a functional substrate binding site and catalytic pocket (Figure 1c). In Plm, the heavy chain (N-terminal domains, 63 kDa) and the light chain (SP domain, 25 kDa) are linked together by two disulfide bonds, between Cys558-Cys566 and Cys548-Cys666.

Serine protease inhibitors (termed serpins [27]) play a key regulatory role to ensure that there is no aberrant activation of Plg nor free Plm in the circulation. Under physiological conditions, the activity of plasminogen activators is modulated by their specific plasminogen activator inhibitors (PAI-1 and PAI-2) (Figure 1b) [28]. Active Plm which is not physically immobilized is removed immediately from the circulation by Plm-specific inhibitor α2-antiplasmin (α2-AP) [29, 30].


3. Streptokinase

3.1 Structure and function of SK

SK is secreted by GAS as a 47 kDa protein and consists of three homologous domains, termed α, β, and γ, held together by flexible linker loops. Each domain adopts a β-grasp fold consisting of 4–5-stranded β sheets and a central α-helix or a coiled coil [31]. The interaction between Plg/Plm and SK is evolutionarily conserved and strictly species specific [32, 33]. SK variants secreted by GAS isolated from different species (e.g., from human, pig, and horse) are incapable of any cross-species reactivity and therefore are predicted to share not only low sequence identity but also low structural homology [32].

The X-ray crystallography studies on the binary complex of Plm SP domain (μPlm) and SK reveal that SK wraps around the SP domain forming a horseshoe-shaped structure [31, 34] (Figure 2) and further superposition of the full-length closed Plg with the μPlm-SK structures suggests that the interaction between SK and Plg can occur with Plg, which remains in its closed conformation without any steric clashes (Figure 2) [35]. This observation provides fundamental insights to the mode of Plg activation by SK, as discussed in the next section.

Figure 2.

Crystal structure of SK-μPlg and in silico docking model of SK-Plg encounter complex (left panel). Structure of SK-μPlg (Plg SP domain) complex (PDB ID: 1BML) [31]. SK α, β, and γ domains are colored blue, pink and green, respectively, whereas μPlg is shown in orange. (Middle panel) Superposition of the SK-μPlg structure and (right panel) full-length Plg generate the structural model of SK-Plg encounter complex. This model suggests that the SK can bind to closed Plg without any steric interference. Dashed circle highlights the proposed Plg substrate binding region (250-loop) in the β domain of SK.

SK is not a protease, nor it activates Plg by proteolytically cleaving the activation loop as uPA or tPA mentioned above. It forms a 1:1 stoichiometric complex with Plg through a rapid binding reaction, with an association rate of 5.4 × 107 M−1 s−1 [36]. Binding of SK to free Plg results in the formation of catalytically active Plg (Plg*) (Figure 3). The SK-Plg* binary complex [37, 38] cleaves Plg, either in closed or open conformation, to form Plm.

Figure 3.

Mechanism of SK-mediated Plg activation. (1) The first catalytic (named trigger) cycle is initiated by the binding of free Plg to SK and the generation of the proteolytically active SK-Plg* complex. (2) SK-Plg* activates free Plg substrate to Plm. (3) Plm displaces Plg in the SK-Plg* complex to form the final and irreversible SK-Plm complex. (4) In the second catalytic (named bullet) cycle, the SK-Plm activator complex converts free Plg to Plm at a fast rate.

The Plm generated has a much higher (~57,000-fold) affinity for SK than Plg (KD 11 pM and 624 nM, respectively), such that the Plg in the SK-Plg* complex would be replaced by Plm to form the final and irreversible SK-Plm complex (Figure 3) [39, 40]. The inhibitory capacity of α2-AP reduces significantly with a ~10,000-fold lower affinity for the SK-Plm complex than Plm (rate constant of 1.4 × 102 and 5.4 × 107 M−1 s−1, respectively) [36, 41]; accordingly, GAS infection could potentially generate an unregulated pericellular proteolytic (i.e., Plm) activity within the host.

3.2 Plg activation by SK

How does SK activate Plg without cleaving the activation loop? The current model suggests that the N-terminal Ile1 residue of SK inserts into the binding cleft of Val562 in the SP domain and forms a salt bridge with Asp740. Accordingly, it induces a conformational change and formation of a functional catalytic site [42, 43, 44]. This “molecular sexuality” mechanism of cofactor-induced zymogen activation is also reported in the activation of prothrombin-2 by staphylocoagulase from Staphylococcus aureus [45].

The activation loop of Plg has evolved, via negative selection, to be a poor substrate of Plm [46], to minimize the risks of autoactivation. Binding to SK, however, changes the shape of the substrate binding pocket. In doing so, SK-Plg* and SK-Plm becomes highly specific in the binding and cleavage of the Plg activation loop [47], and this leads to a total deregulation of the fibrinolytic system.

Lastly, how does SK-Plg* or SK-Plm access the activation loop of Plg which is shielded in the closed conformation as previously discussed? Published data suggested that SK mediates a conformational change in the substrate Plg. Specifically, the substrate binding site of SK-Plm is situated at the tip of the protruding 250-loop region (residues Ala251-Ile264) of SK β domain (Figure 2) [34]. Mutation studies reveal that residues Arg253, Lys256, and Lys257 of the same 250-loop can also bind simultaneously to the substrate Plg via its LBS of KR-5 domain [48], forming a ternary complex [31, 49, 50]. Thus, it is foreseeable that SK β domain peels KR-5 away from the PAp domain which leads to the formation of an open Plg with its activation loop exposed.

Further, SK has a 20-fold higher affinity for Plg in the open conformation, presumably due to additional interactions with other KR domains [40, 51]. Specifically, the C-terminal Lys414 of SK γ domain has been shown to interact with KR-4 LBS [52, 53]. Apart from Lys414, other Lys residues located at the β and γ domains might also be involved in binding to other KRs; together they promote a remarkably high-affinity interaction between SK and Plg/Plm in their open conformation [54]. However, without any structural data on the co-complexes of the relevant domains, the exact mechanism of the LBS-dependent interactions remains to be speculative.

3.3 Classification of streptokinase

All invasive GAS strains express SK to enhance dissemination [55, 56] and colonization within the host [57]. Interestingly, the SK alleles are polymorphic and can be subdivided into two phylogenetic lineages based on the highly variable β domain [38], namely, cluster 1 (SK1) and cluster 2 (SK2) (Figure 4a) [38, 58, 59]. The sequence identities of α, β, and γ domains between GAS strains are 77, 55, and 84%, respectively [60]. GAS from different clusters show different properties in Plg activation, receptor expression, and receptor binding.

Figure 4.

(a) Allelic variants of streptokinase (SK) from GAS. Sequence alignment of cluster 1, 2a and 2b SK clinical isolates. α, β, and γ domain regions are colored blue, pink, and green, respectively. “*,” “:,” and “.” denote for strictly conserved, strongly similar, and weakly similar residues, respectively. Alignment was performed using the Clustal Omega multiple sequence alignment server (EMBL-EBI). Protein sequence GenBank accession numbers NZ131, ACI61887.1; NS210, AGA54152.1; NS53, AGA54154.1; NS931, AGA54153.1; 5448, AFJ44175.1; NS696, AFJ44174.1; AP53, AGA54155.1; NS223, AGA54156.1; NS455, AGA54157.1; and NS88.2, AGA54158.1. (b) Cartoon illustration of the functional differences of SK clusters. Left: Cluster 1 and 2a SK can directly activate Plg in a 1:1 complex and localize to the bacterial cell surface via plasminogen receptors or indirectly via fibrinogen-binding M protein. Cluster 1 SK-Plm complex is susceptible to α2-AP inhibition. Cluster 2a SK-Plm and cell surface-bound complexes are α2-AP resistant. Right: Cluster 2b SK must first form a ternary complex with fibrinogen (Fg) and Plg before binding onto cell surface via PAM or M protein. Unless bound to PAM, SK-Plg-Fg is inhibited by α2-AP.

SK1-Plg complex is enzymatically active (Figure 4b) but has been shown to be susceptible to α2-AP inhibition [37]. Furthermore, SK1-Plg can bind to fibrinogen (Fg) and form the Fg-SK1-Plg ternary complex without any changes to the enzymatic activity [37]. SK1-Plg binds directly to Plg receptors such as glyceraldehyde-3-phosphate dehydrogenase and enolase, whereas Fg-SK1-Plg binds to M protein receptor such as M1.

SK2 is further subdivided into two clusters—SK2a and SK2b. Like SK1, SK2a expresses M protein and other Plg receptors, and the SK2a-Plg* complex is enzymatically active. One striking difference is that both SK2a-Plg* and SK2a-Plm are resistant to α2-AP inhibition. SK2b on the other hand is co-expressed with a specific Plg receptor called plasminogen-binding group A streptococcal M-like protein (PAM, see next section) [38, 59]. SK2b has a lower affinity for Plg (30-fold lower than SK1 and SK2a) [37], and the SK2b-Plg complex is enzymatically inactive. Thus, Plg activation by SK2b is strictly limited to the bacterial cell surface [61]. Upon formation of the quaternary complex of PAM-SK2b-Plg-Fg, this complex is resistant to α2-AP (Figure 4b).

The polymorphism and functional differences between the SK variants result in different physiopathology of streptococcal infection [59]. For example, the PAM-expressing SK2b strains where Plm activity is restricted to the cell surface are able to sustain much longer-lasting skin infections [37, 62].


4. Plg-binding group A streptococcal M-like protein (PAM)

M protein is the major virulence determinant of GAS [63]. It belongs to a family of dimeric coiled-coil surface-associated proteins. Under the electron microscope, it appears as a fibrillar coat on the bacteria surface [64]. The protein sequence of M proteins is highly variable especially in the first 50 residues at the N-terminus, known as the hypervariable region (HVR). Strain typing based on HVR sequence has identified more than 250 M subtype to date [65]. The variable region confers affinity to different host molecules, such as Fg [66], immunoglobulin [67], complement factor H [68], etc. There has been a number of reviews published on the sequence pattern and function of the M protein family [64, 69] and therefore will not be covered in the current paper. Here, we will focus on the structure and function of PAM, which is a specific Plg receptor that mediates Plg activation by SK2b.

4.1 Structure of PAM

PAM is encoded by the emm gene situated in the multiple gene activator (mga) regulon. The mga regulon contains varying number of emm or emm-like genes and forms the basis of the five different emm patterns (type A-E). PAM-positive GAS strains are exclusively emm pattern D [70, 71].

PAM has the overall domain architecture of an M protein, which includes a hypervariable region (HVR) at the N-terminus followed by variable A and B repeat domains and the conserved C and D domains and an anchor region (Figure 5a). In the precursor protein, there is a signal sequence that precedes the HVR and is removed upon secretion. The anchor region consists of an LPTXG motif that is responsible for sortase-mediated crosslinking of the C-terminus to the cell wall peptidoglycan [64].

Figure 5.

(a) PAM variants from emm pattern D GAS strains. Sequence alignment of PAM variants shown is divided into three classes: I, II, and III. RH motifs in a1 and a2 repeats are highlighted in red, and the three-residue insertions between a1 and a2 in class III PAM are highlighted in blue. For clarity, residues before signal sequence and after sortase sequence were removed. “*,” “:,” and “.” denote strictly conserved, strongly similar, and weakly similar residues, respectively. Alignment was performed using the Clustal Omega multiple sequence alignment server (EMBL-EBI). Protein sequence GenBank accession numbers AP53, CAA80222.1; NS13, AAQ64521.2; NS59, AAQ64518.2; NS10, AAQ64516.2; NS50.1, AAQ64519.3; AlaB49, AEQ25265.1; NS88.2, AAQ64526.2; NS223, AAQ64524.2; NS455, AAQ64527.2; NS1133, AAQ64517.2; NS265, AAQ64525.2; NS221, AAZ66743.1; NS253, AAQ64523.2; NS53, AAQ64522.3; and NS32, AAQ64520.2. (b) Cartoon illustration of the conformational change of PAM and Plg binding. It is proposed that the N-terminal portion of PAM (from HVR to B domain) is largely disordered and transforms to a helical structure upon binding to Plg. The structural change serves to enhance the intermolecular interactions.

To date, no binding target or function has been assigned to the HVR region. However, as this region extends the farthest from the cell surface, it might serve as a hypermutatable decoy which promotes GAS evasion from the host immunity as observed for the HVR of M1 and M5 proteins [72].

The A repeat domain consists of up to two tandem repeats termed a1 and a2. The a1a2 repeats each harbor a conserved Plg-binding motif consisting of an arginine-histidine dipeptide (termed the RH motif). PAM variants differ mainly in the HVR and A repeat region [71] and can be divided into three classes based on the A domain arrangements, namely, I, II, and III (Figure 5a). All classes have the a2 repeat, class I has both a1a2 repeats, class II only has a2, and class III has both a1a2 repeats as in class I, but the repeats are separated by a three-residue insertion. In bacterial strains such as PAMNS265 and PAMNS32, the second RH motif is mutated to Arg-Tyr and Gly-His, respectively (Figure 5a). Despite these variations, all PAM bind to human Plg with high affinities [71, 73, 74].

Based on NMR studies [74], the structure of the HVR and A domain is predominantly disordered, and the binding to Plg results in a major conformational change and formation of α-helical structures (Figure 5b). This observation was further supported by experimental data published in a recent study [75], where it is revealed that the conformation switch can be detected even without binding to Plg, and the alternation between disordered and a dimeric α-helical structure occurs in a temperature-dependent manner, similar to the M1 protein reported previously [76]. This observation could be explained by a conformation sampling of the flexible domains.

Other than the aforementioned dynamic and dimeric interaction at the N-terminal HVR and A domains, the current structure model of PAM is a coiled-coil dimer, which is stabilized via the C and D domains’ interaction [74]. It is proposed that at least two C domains are required for a stable dimer formation. However, PAMNS455, one of the smallest PAM variants identified to date, contains only one C domain (Figure 5a). While it has been shown that PAMNS455 has high affinity for Plg [71], the question remains if and how PAMNS455 maintains the dimeric assembly.

4.2 Binding mechanism of PAM to Plg

PAM binds to both Plg and Plm directly with high affinity (KD of ~1 nM) [77, 78] through the RH motifs in the A repeat region to Plg KR2 domain (Figure 6) [79]. Based on the crystal structures of the a1 repeat-KR2 binary complex, the side chains of the RH motif residues Arg101 and His102 form a pseudo-lysine moiety (called the lysine isostere) and bind to the LBS of KR2 [79, 80]. Peripheral residues of the RH motif such as Asp91, Glu93, Leu97, Lys98, and Glu104 mediate further intermolecular interaction via binding to residues of KR2 outside the LBS, namely, Tyr200, Arg220, Arg234, and Trp235 [80]. These additional interactions play important roles in stabilization of the complex. Of these residues, Tyr200 and Arg220 are unique to KR2, accordingly; these residues may drive the specificity of the A repeats toward the KR2 domain. In doing so, PAM is expected to bind not only tightly to Plg but also without competing with SK binding [80]. Further structural studies would be required to validate this hypothesis.

Figure 6.

X-ray crystal structure of angiostatin (KR1-KR2) and VEK-30 complex (PDB ID 2DOI). VEK-30 (magenta), a peptide derived from PAM AP53, binds to KR2 (brown) primarily by its RH (R101 and H102) motif (sticks) interacting with the LBS residues D219 and E221 (inset). Together, R101, H102, and E104 form a lysine isostere that is recognized by the LBS of KR2. KR1 (light-blue) does not play a role in the complex formation [80].

Outside the A repeats-KR2 binding interface, there are many questions remained to be addressed regarding the interaction between Plg and PAM. For instance, both a1 and a2 were shown to bind KR2 [81], but would a single PAM monomer bind to two Plg? Further, KR2 in closed Plg is inaccessible. How does PAM bind to KR2? Does it induce a conformational change of Plg prior to the complex formation [78]? Furthermore, the N-linked glycosylation of Plg at KR3 in Plg glycoform I reduces its affinity for PAM [82]; does KR3, which does not have a functional LBS, mediate exosite(s) interaction with PAM?


5. Streptococcal inhibitor of complement (SIC)

Streptococcal inhibitor of complement (SIC) is a 31-kDa secreted virulence factor found in M1 and M57 GAS serotypes. SIC is named after its inhibitory function of complement-mediated cell lysis. SIC binds to complement system regulators such as histidine-rich glycoprotein, clusterin, and membrane attack complex C5b-C9 (Figure 7a) [83]. Subsequent research revealed that SIC also binds to antimicrobial peptides [84, 85], extracellular histones [86], fibrin [87], thrombin [87], and plasminogen [87]. Accordingly, the physiological role of SIC is to manipulate the host defense system for infection and invasion. Of particular interest to the current review is that it inhibits the fibrinolytic system through binding to Plg [87].

Figure 7.

(a) Streptococcal inhibitor of complement (SIC), a multifunctional protein, binds to a number of proteins and peptides that are involved in the formation of membrane attack complex [83], activation of contact system [95], antimicrobial activities [96], and clot formation and fibrinolysis [87]. Together, SIC facilitates bacterial survival, colonization, and immune evasion. (b) Sequence alignment of SIC from strains M1 and M57. Sequence alignment shows variability in the number of repeats in the short repeat region (green), whereas the three tandem repeats (1–3) are highly conserved. “*,” “:,” and “.” denote strictly conserved, strongly similar, and weakly similar residues, respectively. Alignment was performed using the Clustal Omega multiple sequence alignment server (EMBL-EBI). Protein sequence GenBank accession numbers M1, AAK34693.1; M1 AP1, AKG28717.1; and M57, AAP31326.1.

5.1 Structure and function of SIC

SIC consists of an N-terminal signal peptide that is cleaved upon secretion; the mature form has a short repeat region followed by three tandem repeats of about 30 residues each (Figure 7b). The three-dimensional structure of SIC is currently unknown, and there is no apparent sequence identity with proteins in the database such as Pfam.

Additional to its well-known roles in suppressing the host defense system, SIC has been shown to modulate the fibrinolytic system [87]. It was proposed that SIC inhibits SK-mediated Plg activation. Specifically, SIC-positive GAS entrapped in the fibrin clot allows its survival for much longer than the SIC-negative strain. The entrapped bacteria colonize before its dissemination from the primary infection sites.

SIC is expressed in the early growth phase of M1 GAS; its role, which is to temporally regulate the activity of SK, is only reported in a recent study. It was shown that the Plg-binding motif(s) in SIC is located at the C-terminal 200 residues which presumably binds the Plg KR domains [87]. Significantly, although SIC does not bind to Plm, it binds specifically to Plg via competing with SK for Plg. It remains to be determined experimentally whether the C-terminal domain of SIC also binds to the Plg KR5 and/or the SP domains like SK, as discussed previously.


6. Conclusion

The fibrin network plays a pivotal role in innate immune defense via entrapping pathogens within the primary infection sites. GAS infection studies in animals have provided strong evidence that GAS has the ability to manipulate the host fibrinolytic system at many levels [88, 89]. On one hand, hijacking the host Plg/Plm on the bacterial surface has provided an energy-efficient strategy to break down the fibrin network during dissemination [55, 57, 90], and this is achieved with the aid of PAM. Using GAS strains which express both SK2b and PAM genes, it was shown that inactivation of either genes significantly reduces virulence [59]. SIC, on the other hand, allows the bacteria to make use of the fibrin network as a shelter during the initial colonization phase, and it simultaneously inhibits the complement system in order to ensure the survival of bacteria in the early infection phase. The combined effects of these virulent factors perhaps allow the SIC-expressing M1 strain to be one of most invasive GAS [91].

GAS has evolved into a formidable pathogen through its millennial of coexistence with human host and natural selection; it is invasive and also evasive through manipulating the host immunity with a plethora of virulent factors. The three extracellular virulent factors discussed in this review modulate specifically the fibrinolytic system via an assembly of Plg modulators. Ironically, these virulence factors are capable of outranking the human counterparts in terms of efficiencies and affinities. SK, for instance, is the most efficacious Plg activator ever discovered, and therefore it was the first therapeutic approved for the treatment of thrombotic disorders including myocardial infarction [92] and pulmonary embolism [93]. With the increasing prevalence of antibiotic-resistant superbugs, GAS infection is expected to post a risk to public health worldwide. Better understanding on the molecular mechanisms of how these virulent factors manipulate the host immunity will provide insight on future development of treatments for GAS infection.



This work was supported in part by the Australian National Health Medical Research Council. J. C. W. is an Australian Laureate Research Fellow.


Conflict of interest

There is no conflict of interest.


  1. 1. Ralph AP, Carapetis JR. Group A streptococcal diseases and their global burden. Current Topics in Microbiology and Immunology. 2013;368:1-27
  2. 2. Cunningham MW. Post-streptococcal autoimmune sequelae: Rheumatic fever and beyond. In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus Pyogenes: Basic Biology to Clinical Manifestations. The University of Oklahoma Health Sciences Center; 2016. pp. 893-930
  3. 3. Chaturvedi S, Boyd R, Krause V. Acute post-streptococcal glomerulonephritis in the Northern Territory of Australia: A review of data from 2009 to 2016 and comparison with the literature. The American Journal of Tropical Medicine and Hygiene. 2018;99:1643-1648
  4. 4. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. The Lancet Infectious Diseases. 2005;5:685-694
  5. 5. Sims Sanyahumbi A, Colquhoun S, Wyber R, Carapetis JR. Global disease burden of group A streptococcus. In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus Pyogenes: Basic Biology to Clinical Manifestations. 2016. pp. 661-704
  6. 6. Sanderson-Smith ML, De Oliveira DM, Ranson M, McArthur JD. Bacterial plasminogen receptors: Mediators of a multifaceted relationship. Journal of Biomedicine & Biotechnology. 2012;2012:272148. DOI: 10.1155/2012/272148
  7. 7. Verhamme IM, Panizzi PR, Bock PE. Pathogen activators of plasminogen. Journal of Thrombosis and Haemostasis. 2015;13:S106-S114. DOI: 10.1111/jth.12939
  8. 8. Lahteenmaki K, Kuusela P, Korhonen TK. Bacterial plasminogen activators and receptors. FEMS Microbiology Reviews. 2001;25:531-552
  9. 9. Korhonen TK. Fibrinolytic and procoagulant activities of Yersinia pestis and salmonella enterica. Journal of Thrombosis and Haemostasis. 2015;13:S115-S120. DOI: 10.1111/jth.12932
  10. 10. Sherry S. Personal reflections on the development of thrombolytic therapy and its application to acute coronary thrombosis. American Heart Journal. 1981;102:1134-1138
  11. 11. Tillett WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. The Journal of Experimental Medicine. 1933;58:485-502
  12. 12. Christensen LR, Macleod CM. A proteolytic enzyme of serum: Characterization, activation, and reaction with inhibitors. The Journal of General Physiology. 1945;28:559-583
  13. 13. Kunitz M. Formation of trypsin from trypsinogen by an enzyme produced by a mold of the genus Penicillium. The Journal of General Physiology. 1938;21:601-620
  14. 14. Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochimica et Biophysica Acta. 1985;823:35-65
  15. 15. Romer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, et al. Plasminogen and wound healing. Nature Medicine. 1996;2:725
  16. 16. Ploplis VA, French EL, Carmeliet P, Collen D, Plow EF. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood. 1998;91:2005-2009
  17. 17. Bai H, Nangia S, Parmer RJ. The plasminogen activation system and the regulation of catecholaminergic function. Journal of Biomedicine and Biotechnology. 2012;2012:721657
  18. 18. Raum D, Marcus D, Alper CA, Levey R, Taylor PD, Starzl TE. Synthesis of human plasminogen by the liver. Science. 1980;208:1036-1037
  19. 19. Novokhatny VV, Kudinov SA, Privalov PL. Domains in human plasminogen. Journal of Molecular Biology. 1984;179:215-232
  20. 20. Castellino FJ, Powell JR. Human plasminogen. Methods in Enzymology. 1981;80:365-378
  21. 21. Law RH, Caradoc-Davies T, Cowieson N, Horvath AJ, Quek AJ, Encarnacao JA, et al. The X-ray crystal structure of full-length human plasminogen. Cell Reports. 2012;1:185-190. DOI: 10.1016/j.celrep.2012.1002.1012
  22. 22. Miles LA, Dahlberg CM, Plow EF. The cell-binding domains of plasminogen and their function in plasma. The Journal of Biological Chemistry. 1988;263:11928-11934
  23. 23. Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell type. The Journal of Cell Biology. 1986;103:2411-2420
  24. 24. Tsurupa G, Medved L. Fibrinogen alpha C domains contain cryptic plasminogen and tPA binding sites. Annals of the New York Academy of Sciences. 2001;936:328-330
  25. 25. Summaria L, Hsieh B, Robbins KC. The specific mechanism of activation of human plasminogen to plasmin. The Journal of Biological Chemistry. 1967;242:4279-4283
  26. 26. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. Journal of Biological Chemistry. 1982;257:2912-2919
  27. 27. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski memorial lecture. Thrombosis and Haemostasis. 1980;43:77-89
  28. 28. Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, van Zonneveld AJ, et al. Endothelial plasminogen activator inhibitor (PAI): A new member of the Serpin gene family. The EMBO Journal. 1986;5:2539-2544
  29. 29. Coughlin PB. Antiplasmin: The forgotten serpin? FEBS Journal. 2005;272:4852-4857
  30. 30. Lu BGC. Analysis of the interaction between α2-antiplasmin and plasmin(ogen) [Doctor of Philosophy thesis]. Australian Centre for Blood Diseases, Monash University; 2013
  31. 31. Wang X, Lin X, Loy JA, Tang J, Zhang XC. Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. Science. 1998;281:1662-1665
  32. 32. Caballero AR, Lottenberg R, Johnston KH. Cloning, expression, sequence analysis, and characterization of streptokinases secreted by porcine and equine isolates of Streptococcus equisimilis. Infection and Immunity. 1999;67:6478-6486
  33. 33. Gladysheva IP, Turner RB, Sazonova IY, Liu L, Reed GL. Coevolutionary patterns in plasminogen activation. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:9168-9172
  34. 34. Wang X, Tang J, Hunter B, Zhang XC. Crystal structure of streptokinase beta-domain. FEBS Letters. 1999;459:85-89
  35. 35. Law RH, Abu-Ssaydeh D, Whisstock JC. New insights into the structure and function of the plasminogen/plasmin system. Current Opinion in Structural Biology. 2013;23:836-841. DOI: 10.1016/
  36. 36. Cederholm-Williams SA, De Cock F, Lijnen HR, Collen D. Kinetics of the reactions between streptokinase, plasmin and alpha 2-antiplasmin. European Journal of Biochemistry. 1979;100:125-132
  37. 37. Cook SM, Skora A, Gillen CM, Walker MJ, McArthur JD. Streptokinase variants from Streptococcus pyogenes isolates display altered plasminogen activation characteristics—Implications for pathogenesis. Molecular Microbiology. 2012;86:1052-1062. DOI: 10.1111/mmi.12037
  38. 38. McArthur JD, McKay FC, Ramachandran V, Shyam P, Cork AJ, Sanderson-Smith ML, et al. Allelic variants of streptokinase from Streptococcus pyogenes display functional differences in plasminogen activation. The FASEB Journal. 2008;22:3146-3153. DOI: 10.1096/fj.3108-109348
  39. 39. Boxrud PD, Fay WP, Bock PE. Streptokinase binds to human plasmin with high affinity, perturbs the plasmin active site, and induces expression of a substrate recognition exosite for plasminogen. The Journal of Biological Chemistry. 2000;275:14579-14589
  40. 40. Boxrud PD, Bock PE. Coupling of conformational and proteolytic activation in the kinetic mechanism of plasminogen activation by streptokinase. The Journal of Biological Chemistry. 2004;279:36642-36649
  41. 41. Wiman B. On the reaction of plasmin or plasmin-streptokinase complex with aprotinin or α2-antiplasmin. Thrombosis Research. 1980;17:143-152
  42. 42. Reddy KN, Markus G. Mechanism of activation of human plasminogen by streptokinase. Presence of active center in streptokinase-plasminogen complex. The Journal of Biological Chemistry. 1972;247:1683-1691
  43. 43. Boxrud PD, Verhamme IM, Fay WP, Bock PE. Streptokinase triggers conformational activation of plasminogen through specific interactions of the amino-terminal sequence and stabilizes the active zymogen conformation. The Journal of Biological Chemistry. 2001;276:26084-26089
  44. 44. Wang S, Reed GL, Hedstrom L. Deletion of Ile1 changes the mechanism of streptokinase: Evidence for the molecular sexuality hypothesis. Biochemistry. 1999;38:5232-5240
  45. 45. Friedrich R, Panizzi P, Fuentes-Prior P, Richter K, Verhamme I, Anderson PJ, et al. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature. 2003;425:535-539
  46. 46. Hervio LS, Coombs GS, Bergstrom RC, Trivedi K, Corey DR, Madison EL. Negative selectivity and the evolution of protease cascades: The specificity of plasmin for peptide and protein substrates. Chemistry & Biology. 2000;7:443-453
  47. 47. Parry MA, Zhang XC, Bode I. Molecular mechanisms of plasminogen activation: Bacterial cofactors provide clues. Trends in Biochemical Sciences. 2000;25:53-59
  48. 48. Tharp AC, Laha M, Panizzi P, Thompson MW, Fuentes-Prior P, Bock PE. Plasminogen substrate recognition by the streptokinase-plasminogen catalytic complex is facilitated by Arg253, Lys256, and Lys257 in the streptokinase beta-domain and kringle 5 of the substrate. The Journal of Biological Chemistry. 2009;284:19511-19521. DOI: 10.11074/jbc.M19109.005512
  49. 49. Alkjaersig N, Fletcher AP, Sherry S. Xi-Aminocaproic acid: An inhibitor of plasminogen activation. The Journal of Biological Chemistry. 1959;234:832-837
  50. 50. Young KC, Shi GY, Wu DH, Chang LC, Chang BI, Ou CP, et al. Plasminogen activation by streptokinase via a unique mechanism. The Journal of Biological Chemistry. 1998;273:3110-3116
  51. 51. Boxrud PD, Bock PE. Streptokinase binds preferentially to the extended conformation of plasminogen through lysine binding site and catalytic domain interactions. Biochemistry. 2000;39:13974-13981
  52. 52. Panizzi P, Boxrud PD, Verhamme IM, Bock PE. Binding of the COOH-terminal lysine residue of streptokinase to plasmin(ogen) kringles enhances formation of the streptokinase plasmin(ogen) catalytic complexes. The Journal of Biological Chemistry. 2006;281:26774-26778
  53. 53. Verhamme IM, Bock PE. Rapid-reaction kinetic characterization of the pathway of streptokinase-plasmin catalytic complex formation. The Journal of Biological Chemistry. 2008;283:26137-26147. DOI: 10.21074/jbc.M804038200
  54. 54. Verhamme IM, Bock PE. Rapid binding of plasminogen to streptokinase in a catalytic complex reveals a three-step mechanism. The Journal of Biological Chemistry. 2014;289:28006-28018. DOI: 10.21074/jbc.M28114.589077
  55. 55. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, Yang AY, et al. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science. 2004;305:1283-1286
  56. 56. Nitzsche R, Rosenheinrich M, Kreikemeyer B, Oehmcke-Hecht S. Streptococcus pyogenes triggers activation of the human contact system by streptokinase. Infection and Immunity. 2015;83:3035-3042. DOI: 10.1128/IAI.00180-00115
  57. 57. Nitzsche R, Kohler J, Kreikemeyer B, Oehmcke-Hecht S. Streptococcus pyogenes escapes killing from extracellular histones through plasminogen binding and activation by streptokinase. Journal of Innate Immunity. 2016;8:589-600
  58. 58. Kapur V, Kanjilal S, Hamrick MR, Li LL, Whittam TS, Sawyer SA, et al. Molecular population genetic analysis of the streptokinase gene of Streptococcus pyogenes: Mosaic alleles generated by recombination. Molecular Microbiology. 1995;16:509-519
  59. 59. Kalia A, Bessen DE. Natural selection and evolution of streptococcal virulence genes involved in tissue-specific adaptations. Journal of Bacteriology. 2004;186:110-121
  60. 60. Zhang Y, Liang Z, Glinton K, Ploplis VA, Castellino FJ. Functional differences between Streptococcus pyogenes cluster 1 and cluster 2b streptokinases are determined by their beta-domains. FEBS Letters. 2013;587:1304-1309. DOI: 10.1016/j.febslet.2013.1302.1033
  61. 61. Cook SM, Skora A, Walker MJ, Sanderson-Smith ML, McArthur JD. Site restricted plasminogen activation mediated by group A streptococcal streptokinase variants. The Biochemical Journal. 2013;22:22
  62. 62. Bessen DE, Sotir CM, Readdy TL, Hollingshead SK. Genetic correlates of throat and skin isolates of group A streptococci. The Journal of Infectious Diseases. 1996;173:896-900
  63. 63. Lancefield RC. Current knowledge of type-specific M antigens of group A streptococci. Journal of Immunology. 1962;89:307-313
  64. 64. Fischetti VA. M protein and other surface proteins on streptococci. In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus Pyogenes: Basic Biology to Clinical Manifestations. Oklahoma City, OK: The University of Oklahoma Health Sciences Center; 2016. pp. 27-54
  65. 65. McMillan DJ, Dreze PA, Vu T, Bessen DE, Guglielmini J, Steer AC, et al. Updated model of group A streptococcus M proteins based on a comprehensive worldwide study. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2013;19:E222-E229
  66. 66. Glinton K, Beck J, Liang Z, Qiu C, Lee SW, Ploplis VA, et al. Variable region in streptococcal M-proteins provides stable binding with host fibrinogen for plasminogen-mediated bacterial invasion. The Journal of Biological Chemistry. 2017;292:6775-6785
  67. 67. Hong K. Human IgG binding ability of streptococcal M3 protein: Its related complement activation-dependent M3 protein polymerization. FEMS Immunology and Medical Microbiology. 1997;18:163-174
  68. 68. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA. Antiphagocytic activity of streptococcal M protein: Selective binding of complement control protein factor H. Proceedings of the National Academy of Sciences of the United States of America. 1988;85:1657-1661
  69. 69. Ghosh P. Variation, indispensability, and masking in the M protein. Trends in Microbiology. 2018;26:132-144
  70. 70. Sanderson-Smith ML, Walker MJ, Ranson M. The maintenance of high affinity plasminogen binding by group A streptococcal plasminogen-binding M-like protein is mediated by arginine and histidine residues within the a1 and a2 repeat domains. The Journal of Biological Chemistry. 2006;281:25965-25971
  71. 71. Sanderson-Smith M, Batzloff M, Sriprakash KS, Dowton M, Ranson M, Walker MJ. Divergence in the plasminogen-binding group A streptococcal M protein family: Functional conservation of binding site and potential role for immune selection of variants. The Journal of Biological Chemistry. 2006;281:3217-3226
  72. 72. Lannergard J, Gustafsson MC, Waldemarsson J, Norrby-Teglund A, Stalhammar-Carlemalm M, Lindahl G. The hypervariable region of Streptococcus pyogenes M protein escapes antibody attack by antigenic variation and weak immunogenicity. Cell Host & Microbe. 2011;10:147-157
  73. 73. Yuan Y, Zajicek J, Qiu C, Chandrahas V, Lee SW, Ploplis VA, et al. Conformationally organized lysine isosteres in Streptococcus pyogenes M protein mediate direct high-affinity binding to human plasminogen. The Journal of Biological Chemistry. 2017;292:15016-15027
  74. 74. Qiu C, Yuan Y, Zajicek J, Liang Z, Balsara RD, Brito-Robionson T, et al. Contributions of different modules of the plasminogen-binding Streptococcus pyogenes M-protein that mediate its functional dimerization. Journal of Structural Biology. 2018;204:151-164
  75. 75. Qiu C, Yuan Y, Liang Z, Lee SW, Ploplis VA, Castellino FJ. Variations in the secondary structures of PAM proteins influence their binding affinities to human plasminogen. Journal of Structural Biology. 1 May 2019;206(2):193-203
  76. 76. McNamara C, Zinkernagel AS, Macheboeuf P, Cunningham MW, Nizet V, Ghosh P. Coiled-coil irregularities and instabilities in group A streptococcus M1 are required for virulence. Science. 2008;319:1405-1408
  77. 77. Berge A, Sjobring U. PAM, a novel plasminogen-binding protein from Streptococcus pyogenes. The Journal of Biological Chemistry. 1993;268:25417-25424
  78. 78. Bhattacharya S, Liang Z, Quek AJ, Ploplis VA, Law R, Castellino FJ. Dimerization is not a determining factor for functional high affinity human plasminogen binding by the group A streptococcal virulence factor PAM and is mediated by specific residues within the PAM a1a2 domain. The Journal of Biological Chemistry. 2014;289:21684-21693. DOI: 10.21074/jbc.M21114.570218
  79. 79. Rios-Steiner JL, Schenone M, Mochalkin I, Tulinsky A, Castellino FJ. Structure and binding determinants of the recombinant kringle-2 domain of human plasminogen to an internal peptide from a group A streptococcal surface protein. Journal of Molecular Biology. 2001;308:705-719
  80. 80. Cnudde SE, Prorok M, Castellino FJ, Geiger JH. X-ray crystallographic structure of the angiogenesis inhibitor, angiostatin, bound to a peptide from the group A streptococcal surface protein PAM. Biochemistry. 2006;45:11052-11060
  81. 81. Quek AJH, Mazzitelli BA, Wu G, Leung EWW, Caradoc-Davies TT, Lloyd GJ, et al. Structure and Function Characterization of the a1a2 Motifs of Streptococcus pyogenes M Protein in Human Plasminogen Binding. Journal Molelcular Biology. 2019;2836(19)30424-304330
  82. 82. De Oliveira DM, Law RH, Ly D, Cook SM, Quek AJ, McArthur JD, et al. Preferential acquisition and activation of plasminogen glycoform II by PAM positive group A streptococcal isolates. Biochemistry. 2015;54:3960-3968. DOI: 10.1021/acs.biochem.3965b00130
  83. 83. Akesson P, Sjoholm AG, Bjorck L. Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function. The Journal of Biological Chemistry. 1996;271:1081-1088
  84. 84. Frick IM, Akesson P, Rasmussen M, Schmidtchen A, Bjorck L. SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. The Journal of Biological Chemistry. 2003;278:16561-16566
  85. 85. Fernie-King BA, Seilly DJ, Lachmann PJ. The interaction of streptococcal inhibitor of complement (SIC) and its proteolytic fragments with the human beta defensins. Immunology. 2004;111:444-452
  86. 86. Westman J, Chakrakodi B, Snall J, Morgelin M, Bruun Madsen M, Hyldegaard O, et al. Protein SIC secreted from Streptococcus pyogenes forms complexes with extracellular histones that boost cytokine production. Frontiers in Immunology. 2018;9:236
  87. 87. Frick IM, Shannon O, Neumann A, Karlsson C, Wikstrom M, Bjorck L. Streptococcal inhibitor of complement (SIC) modulates fibrinolysis and enhances bacterial survival within fibrin clots. The Journal of Biological Chemistry. 2018;293:13578-13591
  88. 88. Li Z, Ploplis VA, French EL, Boyle MD. Interaction between group A streptococci and the plasmin(ogen) system promotes virulence in a mouse skin infection model. The Journal of Infectious Diseases. 1999;179:907-914
  89. 89. Khil J, Im M, Heath A, Ringdahl U, Mundada L, Cary Engleberg N, et al. Plasminogen enhances virulence of group A streptococci by streptokinase-dependent and streptokinase-independent mechanisms. The Journal of Infectious Diseases. 2003;188:497-505
  90. 90. Sumitomo T, Nakata M, Higashino M, Yamaguchi M, Kawabata S. Group A streptococcus exploits human plasminogen for bacterial translocation across epithelial barrier via tricellular tight junctions. Scientific Reports. 2016;7:20069
  91. 91. Chatellier S, Ihendyane N, Kansal RG, Khambaty F, Basma H, Norrby-Teglund A, et al. Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infection and Immunity. 2000;68:3523-3534
  92. 92. Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Transactions of the Association of American Physicians. 1958;71:287-296
  93. 93. Hirsh J, Hale GS, McDonald IG, McCarthy RA, Cade JF. Resolution of acute massive pulmonary embolism after pulmonary arterial infusion of streptokinase. The Lancet. 1967;2:593-597
  94. 94. Millers EKI, Johnson LA, Birrell GW, Masci PP, Lavin MF, de Jersey J, et al. The structure of human microplasmin in complex with Textilinin-1, an Aprotinin-like inhibitor from the Australian Brown Snake. PLoS One. 2013;8(1):e54104. DOI: 10.1371/journal.pone.0054104. [Epub 2013 Jan 15]
  95. 95. Akesson P, Herwald H, Rasmussen M, Hakansson K, Abrahamson M, Hasan AA, et al. Streptococcal inhibitor of complement-mediated lysis (SIC): An anti-inflammatory virulence determinant. Microbiology. 2010;156:3660-3668
  96. 96. Frick IM, Shannon O, Akesson P, Morgelin M, Collin M, Schmidtchen A, et al. Antibacterial activity of the contact and complement systems is blocked by SIC, a protein secreted by Streptococcus pyogenes. The Journal of Biological Chemistry. 2011;286:1331-1340

Written By

Adam J.H. Quek, James C. Whisstock and Ruby H.P. Law

Submitted: 31 December 2018 Reviewed: 22 June 2019 Published: 14 August 2019